Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

A Study of V132 in Healthy Older Participants (V132-001)

17 oktober 2026 uppdaterad av: Merck Sharp & Dohme LLC

A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants

The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

280

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • California
      • Anaheim, California, Förenta staterna, 92801
        • Rekrytering
        • Anaheim Clinical Trials ( Site 0006)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 714-774-7777
    • Florida
      • Hallandale, Florida, Förenta staterna, 33009
        • Rekrytering
        • Velocity Clinical Research, Hallandale Beach ( Site 0003)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 954-455-5757
      • Hollywood, Florida, Förenta staterna, 33024
        • Rekrytering
        • Research Centers of America ( Hollywood ) ( Site 0009)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 954-990-7649
      • South Miami, Florida, Förenta staterna, 33143
        • Rekrytering
        • QPS-MRA, LLC-Early Phase ( Site 0001)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 305-722-0970
    • Missouri
      • Springfield, Missouri, Förenta staterna, 65802
        • Rekrytering
        • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 417-831-2048
    • Nebraska
      • Lincoln, Nebraska, Förenta staterna, 68510
        • Rekrytering
        • Velocity Clinical Research Lincoln ( Site 0007)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 531-530-2800
      • Omaha, Nebraska, Förenta staterna, 68134
        • Rekrytering
        • Velocity Clinical Research, Omaha ( Site 0008)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 402-933-6500
    • Ohio
      • Columbus, Ohio, Förenta staterna, 43215
        • Rekrytering
        • Remington-Davis, Inc. ( Site 0005)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 614-487-2560
    • Rhode Island
      • East Greenwich, Rhode Island, Förenta staterna, 02818
        • Rekrytering
        • Velocity Clinical Research, Providence ( Site 0010)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 401-739-9350
    • Texas
      • League City, Texas, Förenta staterna, 77573
        • Rekrytering
        • University of Texas Medical Branch ( Site 0004)
        • Kontakt:
          • Study Coordinator
          • Telefonnummer: 832-340-2313

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

50 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has body mass index (BMI) within 18.0 to 35.0 kg/m^2 (inclusive)

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
  • Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Grundläggande vetenskap
  • Tilldelning: Randomiserad
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Part 1: Dose Escalation

Participants will receive single intramuscular (IM) doses of a V132 formulation or comparator regimen at varying dose levels.

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

Experimentell: Part 2: Dose Expansion

Participants will receive single IM doses of a V132 formulation or comparator regimen. Doses will be determined based on review of Part 1 data and will not exceed maximum dose level assessed in Part 1.

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Tidsram: Up to approximately 30 minutes post vaccination

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with immediate reactions occurring within 30 minutes after any vaccination will be reported.

Up to approximately 30 minutes post vaccination
Percentage of Participants with a Solicited Injection-site Adverse Event
Tidsram: Up to approximately 7 days post vaccination

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed are redness/erythema, swelling, and tenderness/pain. The percentage of participants with a solicited injection-site adverse event will be reported.

Up to approximately 7 days post vaccination
Percentage of Participants with a Solicited Systemic Adverse Event
Tidsram: Up to approximately 7 days post vaccination

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The solicited systemic AEs assessed are muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with a solicited systemic adverse event will be reported.

Up to approximately 7 days post vaccination
Percentage of Participants With at Least 1 Unsolicited Adverse Event
Tidsram: Up to approximately 28 days post vaccination

An unsolicited AE is an AE that was not solicited using a vaccination report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with at least 1 unsolicited adverse event will be reported.

Up to approximately 28 days post vaccination
Percentage of Participants with a Serious Adverse Event
Tidsram: Up to approximately 12 months post vaccination

A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs will be reported.

Up to approximately 12 months post vaccination
Percentage of Participants With at Least 1 Medically Attended Adverse Event
Tidsram: Up to approximately 12 months post vaccination

A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with at least 1 MAAE will be reported.

Up to approximately 12 months post vaccination
Percentage of Participants Who Experienced an Adverse Event of Clinical Interest
Tidsram: Up to approximately 12 months post vaccination

Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). The percentage of participants who experienced an adverse event of clinical interest will be reported.

Up to approximately 12 months post vaccination

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)
Tidsram: Up to approximately 28 days post vaccination

Opsonophagocytic activity (OPA) for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). Geometric Mean Titer (GMT) of serotype-specific OPA will be reported.

Up to approximately 28 days post vaccination
Geometric Mean Fold Rise from Baseline of Serotype-specific OPA
Tidsram: Baseline (pre-vaccination) and 28 days post vaccination

The Geometric Mean Fold Rise (GMFR) from baseline in serotype-specific OPA GMTs for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). GMFR is defined as the geometric mean of the ratio of concentration at Day 28 post vaccination divided by concentration at baseline.

Baseline (pre-vaccination) and 28 days post vaccination

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Medical Director, Merck Sharp & Dohme LLC

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

12 augusti 2026

Primärt slutförande (Beräknad)

5 maj 2028

Avslutad studie (Beräknad)

5 maj 2028

Studieregistreringsdatum

Först inskickad

14 juli 2026

Först inskickad som uppfyllde QC-kriterierna

14 juli 2026

Första postat (Faktisk)

17 juli 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

20 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • V132-001
  • V132-001 (Annan identifierare: MSD)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera